everyone. morning, Vince, good Thanks, and
EPS Slide our as well the and quarter review second highlights. results financial to X, on I'll revenue Moving key as
quarter neutral revenues grew on Second a currency comparable X.X% basis.
our were As line the strong was items broadly expectations, two Vince with quarter performance underlying in by quarter brought expectations. that core below our revenues mentioned, business driven slightly in the second our growth. There
hypodermic reflect our demand impact expect adjustments normalized, now First inventory Medication Inventory Solutions in of the in strong the are Delivery results remainder of U.S., business in the our business. levels year. we the for and our distributor
our communicated I the Adjusted regarding of to a and currency X.X% $X.XX that sell has companies in Second, color on grew when geography. also all previously in this through the results devices EPS impacted products. for The of our reflect these was neutral paclitaxel-coated quarter DCB basis. line revenue with expectations This and the FDA's our more I'll use manufacture growth negatively update quarter mid-March you take the results segment in moment impact provide business. on an quarter. by a
to deliver deleverage three of to commitment quarter, our down debt. below paying over second We We $XXX three to continued to track times also on during achieve approximately remain the years. million
the X, X.X%. Medical on increased Medical second or Moving Slide growth. MDS BD revenues quarter X.X%. in revenue review segment grew Revenues Solutions Delivery Medication to I'll
The the year quarter. also in a prior the expected, in As previously the comparison growth quarter tough second U.S. inventory impacted our results adjustments to discussed reflect
we driven Care business MDS access of strength demand in strong Medication grew Management growth strength Solutions the and and vascular in half Outside and Revenues by retail MMS vascular was X.X%. revenues this performance the U.S. second growth fiscal in the However, in devices. expect in dispensing. and management Growth year. Europe grew access in or was by infusion X.X%. strong driven and Diabetes MMS across
benefited businesses, U.S. first from systems Systems the Revenues negatively in ordering rebounded by growth timing growth quarter in and the with of orders. the Pharmaceutical aided quarter expected. X.X%. timing Performance the growth reflects revenue impacted international expected, and in patterns, first as second strengths grew in lower customer quarter in both As the we of which farm
the Revenues second Slide increased the X.X% BD to and Life in turning X, Sciences quarter. segment. Now
expected, over in As headwind more to a typical this flu of season reflects a XXX growth year's year. related flu this points basis season of strength to comparison last the
you're flu timing the As year-over-year aware, the our and severity comparisons. impact season of can
that driven Diagnostic push be Systems MAX of by aided points approximately comparison. a performance a Systems have solid flu and grew by Preanalytical additions sets. BD improved X.X%, supply and recent double-digit button the molecular basis capacity our continues from revenues reflecting declined and the As Underlying growth IDAST tough platform. headwind revenues to XXX was of collection X.X%. result, in Growth
platforms As strengths our was expected, timing the orders the and FACSymphony research strong was partially FACSLyric grew quarter. of benefited first in Growth offsetting this and X.X%. reagents that distributor revenues growth by Biosciences markets. emerging driven
turning Now Slide to the BD and XX, segment. Interventional
Peripheral or an reflects points unfavorable approximately basis Second in grew from X.X%. DCBs. X.X%. underlying On impact Revenues quarter growth revenues was an of hurricane This PI and the increased XXX basis, X.X%. Intervention
stage the DCB quarter underlying in On driven our over revenues for across my emerging year assumptions global the business. entirety reflect this remainder growth of previously business strong grew an our approximately impact results to disease later the the renal by of remarks. in mentioned growth basis, the markets. growth and I'll in provide updated PI X%, end fiscal Our DCB
X.X%. was quarter Second and growth revenue surgery
and comparison driven by the be our in infection our from the Hurricane home we see temperature well Growth Revenues or where synergy to benefits this revenue to in as prior as in in businesses. released a business orders and and Urology unit investments. expected, Urology tough Care, UCC, Maria. Critical includes prevention, when acute performance hernia reflects As following year continue we grew in surgery to the products supply continues back biosurgery for X%. care targeted strong UCC our in management strength continued and Performance
distributor the Slide the adjustments rate below on you to I'll for revenues impact our grew XX. revenues second U.S. growth Now geographic the through reflects our MDS. within and walk DCBs X.X%. of This and is quarter. normal moving inventory
expected. In tough flu addition, comparison this a reflects as
in partially which by all China, Performance emerging across X.X%. XX.X% reflects was solid This driven segments markets X.X%. all on as of in revenues solid grew Moving with by grew to performance the previously markets Europe, in U.S. segment and across reflects driven Europe medical Revenues by lower grew performance offset Revenues market from performance growth discussed. strength the three in Developed in growth X.X%, emerging international. strong and three segments.
In addition, in emerging double-digit benefited from EMA. markets growth
recaps XX, second statement. which quarter Turning to the Slide income
basis. revenues, grew As in comparable a on quarter discussed the X.X%
a details to profit currency. I'll P&L, a in year-over-year, due expense gross impact the grew SSG&A stock profit in of performance was compensation as Moving just down reflects This of market percentage XX.X%. additional revenues X% the moment. gross the additional excluding provide on deferred quarter.
sales of and impacted expected. a of focus benefit compensation and which other deferred underlying invest basis Bard innovation. by also achievement reflects than ongoing continued commitment synergies. to an discipline SSG&A reference, on was cost the plans, R&D revenue of our offset fully your harmonization compensation spending, growing than are from as expenses income Bard's slower our expenses in as X.X%, and unfavorable percentage was timing reflect For On the expense.
currency decreased basis XX to basis As line on or points, a a operating XXX neutral expectations. with result, margins which basis, our was in points
which year in of our XX% at the was expectations was guidance full range. high-end line quarter, rate tax Our in with also the our
dividends expected, in As we $XX million of the quarter. preferred paid
decline a basis. been shares increase prior are the As the year calculation. in is or the on In outstanding versus earnings an a we adjusted not the quarter, preferred X.X% of X.X% included share have neutral $X.XX, currency discussing of per which were shares
due by improvement and gross profit line our for and quarter, anticipated headwinds flu driven to raw negative margin in from materials gross driven the expectations. Slide broad on Now and impact Operating as had continuous profit currencies. strengthening points Currency year-over-year quarter. margin, margin of the and On a other reflects pricing. than XX driven margin second points operating with against XXX initiatives declined quarter improvement our performance basis while decrease on basis in basis, margins mix profit as XX was which basis. dollar offset as lower was a SSG&A in margin and of by well synergies, a in This unfavorable by the our XX.X% revenues, U.S. DCB cost by discussed. the greater increased basis turning points was was quarter. previously operating profit the Gross the in currency or to The neutral flat margins gross XX
guidance. to revenue XXXX on and XX Moving Slide our fiscal year full
As we is we Through right underlying be. half, strong. are discussed, our to expected where the performance we first
of such of Looking our us flu give across in planned drivers these acceleration. there number a that to second in the the half segments fiscal as beyond the our confidence year are comparison
MMS expect MDS recently and growth which access launched continued and and Medical more gain the capturing new by MDS launches in second vascular these across in market. synergy the And several we've of Life and leading the and BDI the as continued revenue X reagents Covera instrument Sciences, are MAX In momentum segment, BD the Within strong Venovo, timing anticipate growth we being and received sales share as benefit driven in portfolio. include performing in several French such our we BD anticipated BD. half. well products WavelinQ, Within Interventional, the product are in
the continued half second in year. in expect also the double-digit China of We growth
due segment, expect While growth X.X% revenue Interventional guidance company we revenue the to to we headwinds, of X.X% X% anticipated total to have DCB to our reaffirmed X%. now growth BD of
reduction Our XX% year. updated the of guidance sales remainder in reflects over DCB a approximately the of
growth revenue X% Medical BD Life BD expect growth to continue of X% X%. to and Sciences X% to of We
strengths markets, growth and in to diversified to in base anticipate in market growth and with also X% America. continue emerging of a low-double-digit and of Latin XX% We X% about driven by growth EMEA China developed
XX to and Now moving year on our XXXX full EPS fiscal Slide guidance.
broad basis, neutral by about reflects points expectation headwind approximately a current partially Our offset XXX XX%. underlying guidance continued XXX performance, will near-term Based EPS expect currencies. and approximately an currency DCBs. This of additional a basis operating of is on performance, the revenue solid related result our we reflects rates, growth driven for points. to other currency against of dollar driven we strong strengthening On a headwinds. headwind expect basis This EPS of by growth by adjusted U.S.
Our rate our current exchange dollar of forecast reflects $X.XX the of euro $X.XX. original to expectation versus
In to in deliver also profit expected addition inventory. we incremental to our of forecast EPS to pressure $XX.XX. adjusted updated attributable reflects $XX.XX All-in,
we've move to on, In are headwinds facing was we to take offset to encountered headwinds through on investors recent million. the significantly response we've fiscal business. our this before the received the years. year you quarter. prudent of This than total we Now, The like information Slide the thought in questions greater magnitude it year, we've to snapshot the a to headwinds walk headwinds year, I'd is additional this $XXX to amount moment approximately a with to we XX of provided provide this ability
summarize, headwinds ability of the chart greater operating the offset core strong. year, of years. performance. by past in even have deal offset was offset each than integration To track. demonstrates on few this the have together, to driving approximately very We our Bard more $XXX And that is we an to The ability we've XX% robust is much million which this
result revenue detailed and Slide updated approximately also XX%. X% to XX% and expect from be XX to XX, FX pressure. guidance headwinds have of growth DCBs Turning to are FX. between between as basis incremental of a the reflect of points operating We to margins now margins Gross expected X% we reported and our P&L XX% and XX%,
lower FX XX guidance DCB result previous is guidance margin and than headwinds. approximately points Our of a basis our as both
year The remain for expect balance expectations flow unchanged. the to XXXX our guidance $X.X operating fiscal approximately billion. cash We be of full
expect we fiscal year addition, XXXX. In to continue synergies approximately in $XXX million achieve to in cost
we realizing fully We annualized are synergies good cost momentum We track on across businesses. period. over our have year feel in to three the $XXX the million deal about
While in year are our commitments will we're XXXX and we beyond. deliver facing some headwinds, fiscal that confident on near-term
provide Now, who'll to product you the turn back to call our an I'd over portfolio. like Vince, with on update
